EC expands Imcivree approval to acquired hypothalamic obesity

Rhythm Pharmaceuticals said the European Commission has expanded Imcivree’s marketing authorization to cover acquired hypothalamic obesity, clearing the drug for obesity treatment and hunger control in adults and children age 4 and older with hypothalamic injury or impairment. The May 1, 2026 decision makes setmelanotide the first therapy authorized in Europe for this indication, and it follows a positive CHMP opinion in March and a U.S. FDA approval for the same use on March 19, 2026. The company said the EC decision was based on results from the 120-patient cohort of the phase 3 TRANSCEND trial. (globenewswire.com)

Why it matters: This is a human rare-disease obesity approval, not a veterinary one, but it’s still relevant to veterinary professionals tracking the broader obesity-treatment landscape, neuroendocrine drug development, and MC4R-targeted therapies. Setmelanotide has already been marketed for certain rare genetic obesities, and the acquired hypothalamic obesity expansion shows regulators are increasingly willing to back mechanism-based treatments tied to disrupted appetite signaling rather than treating obesity as a single, uniform condition. Earlier phase 2 data and company-reported phase 3 findings suggest the drug’s effect is linked to restoring melanocortin pathway signaling after hypothalamic damage. (ema.europa.eu)

What to watch: Watch for the European label rollout, country-level access and reimbursement decisions, and whether peer-reviewed phase 3 TRANSCEND data sharpen expectations for broader MC4R-pathway programs. (globenewswire.com)